What is BLLN's health score?

BillionToOne, Inc. (BLLN) has a TradeApes health score of 54 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is BLLN's estimated fair value?

Based on our 5-year discounted cash flow model, BillionToOne, Inc.'s estimated fair value is $18.19 per share, representing a -81.3% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is BLLN undervalued or overvalued?

Our model currently rates BLLN as Overvalued. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for BLLN... Refresh in a moment for the full analysis.

BillionToOne, Inc. (BLLN)

Healthcare Overvalued low mixed

$97.19

Updated: 2026-06-06

TradeApes Score

Financial Strength

80 Strong

Operating Trend

50 Mixed

Relative Value

28 Stressed

Capital Allocation

40 Weak

Risk

80 Strong

Est. Fair Value $18.19

DCF Upside -81.3%

Sector Rank #973 of 6986

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Extreme P/E — above 45×, very high expectations embedded in price

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.